The DOI matches its Crossref record.
Incidence of Clinically Significant Responses to Zolpidem Among Patients with Disorders of Consciousness: A Preliminary Placebo Controlled Trial
Abstract
OBJECTIVES: The common hypnotic, zolpidem, has been reported to temporarily restore consciousness to individuals in the chronic vegetative state. In drug responders, repeated dosing appears to maintain consciousness. The frequency of such responses, however, is unknown and is important both to guide clinical use and to plan further research on the mechanisms underlying drug response. The objectives of this study were to obtain an estimate of the frequency of clinically significant responses among individuals with disorders of consciousness, to determine whether less obvious drug responses are present among "nonresponders," and to identify clinical features characteristic of zolpidem responders. DESIGN: Participants were individuals in the vegetative or minimally conscious state at least 1 month after brain injury. Each participant was studied individually in a double-blind, placebo-controlled, crossover design, once on zolpidem (10 mg per feeding tube) and once on placebo. Each assessment involved baseline administration of the Coma Recovery Scale-Revised, followed immediately by administration of the study drug, followed by 5 hourly readministrations of the Coma Recovery Scale-Revised. A replication pair of assessments was available for drug responders. RESULTS: : One of 15 participants (6.7%) demonstrated a clinically significant response, which altered his assessment from the vegetative state to the minimally conscious state, and this result was repeated in the replication assessment. The remaining 14 participants showed no evidence of a subclinical response to the drug. CONCLUSION: These results confirm that clinically significant responses to zolpidem among individuals with disorders of consciousness do occur in a minority of patients and can be replicated. Failure to find a trend toward improved performance on zolpidem among nonresponders suggests a bimodal rather than a graded response to the drug. The fact that only one drug responder was identified in this small study prevents assessment of features characteristic of drug responders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Disorders of consciousness after acquired brain injury: the state of the science
Giacino, J. T., Fins, J. J., Laureys, S., & Schiff, N. D. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.279 · Cited by 883
Recovery of consciousness after brain injury: a mesocircuit hypothesis
Schiff, N. D. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.002 · Cited by 733
The Human Connectome Project and beyond: Initial applications of 300mT/m gradients
McNab, J. A., Edlow, B. L., Witzel, T., Huang, S. Y., Bhat, H., Heberlein, K., Feiweier, T., Liu, K., Keil, B., Cohen-Adad, J., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.074 · Cited by 359
Consciousness in humans and non-human animals: recent advances and future directions
Boly, M., Seth, A. K., Wilke, M., Ingmundson, P., Baars, B., Laureys, S., Edelman, D. B., & Tsuchiya, N. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00625 · Cited by 291
“Amantadine, a dopaminergic drug (Giacino et al., 2012), and surprisingly zolpidem, a GABAergic agonist (Whyte and Myers, 2009), have also proven beneficial in some cases of VS or MCS.”
BackgroundZolpidem for the Treatment of Neurologic Disorders: A Systematic Review
Bomalaski, M. N., Claflin, E. S., Townsend, W., & Peterson, M. D. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1133 · Cited by 83
Metadata
- Authors
- Whyte, J., & Myers, R.
- Venue
- American Journal of Physical Medicine & Rehabilitation
- Published
- 2009-05
- Volume
- 88
- Issue
- 5
- Pages
- 410-418
- ISSN
- 0894-9115 (ISSN-L)
- OpenAlex
- W2007122003
- Cited by
- 172
- References
- 0
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of Clinically Significant Responses to Zolpidem Among Patients with Disorders of Consciousness: A Preliminary Placebo Controlled Trial. https://app.cochat.ai/papers/10.1097/phm.0b013e3181a0e3a0
- The paper
- Whyte, J., & Myers, R. (2009). Incidence of Clinically Significant Responses to Zolpidem Among Patients with Disorders of Consciousness: A Preliminary Placebo Controlled Trial. American Journal of Physical Medicine & Rehabilitation. https://doi.org/10.1097/phm.0b013e3181a0e3a0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.